Hydrogenated Borophene Shows Catalytic Activity as Solid Acid

Hydrogen boride (HB) or hydrogenated borophene sheets are recently realized two-dimensional materials that are composed of only two light elements, boron and hydrogen. However, their catalytic activity has not been experimentally analyzed. Herein, we report the catalytic activity of HB sheets in ethanol reforming. HB sheets catalyze the conversion of ethanol to ethylene and water above 493 K with high selectivity, independent of the contact time, and with an apparent activation energy of 102.8 ± 5.5 kJ/mol. Hence, we identify that HB sheets act as solid-acid catalysts

Effect of Pt nanoparticle decoration on the H2 storage performance of plasma-derived nanoporous graphene

A nanoporous and large surface area (∼800 m2/g) graphene-based material was produced by plasma treatment of natural flake graphite and was subsequently surface decorated with platinum (Pt) nano-sized particles via thermal reduction of a Pt precursor (chloroplatinic acid). The carbon-metal nanocomposite showed a ∼2 wt% loading of well-dispersed Pt nanoparticles (<2 nm) across its porous graphene surface, while neither a significant surface chemistry alteration nor a pore structure degradation was observed due to the Pt decoration procedure. The presence of Pt seems to slightly promote the hydrogen sorption behavior at room temperature with respect to the pure graphene, thus implying the rise of “weak” chemisorption phenomena, including a potential hydrogen “spillover” effect. The findings of this experimental study provide insights for the development of novel graphene-based nanocomposites for hydrogen storage applications at ambient conditions

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

<p>Abstract</p> <p>Background</p> <p>Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC). Few treatment options are available for NSCLC patients who have responded to gefitinib treatment and demonstrated tumor progression. The present study was conducted to evaluate the efficacy and toxicity of the 2^ndEGFR-TKI administration.</p> <p>Methods</p> <p>We retrospectively analyzed 11 patients who had obtained a partial response (PR) or stable disease (SD) with gefitinib treatment and were re-treated with EGFR-TKI after failure of the initial gefitinib treatment.</p> <p>Results</p> <p>Three patients (27%) were treated with gefitinib as the 2^ndEGFR-TKI, and 8 patients (73%) received erlotinib. Only one patient (9%) showed PR, 7 (64%) achieved SD, and 3 (27%) had progressive disease. The disease control rate was 73% (95% CI, 43% - 91%) and the median progression-free survival was 3.4 months (95% CI, 2 - 5.2). The median overall survival from the beginning of the 2^ndEGFR-TKI and from diagnosis were 7.3 months (95% CI, 2.7 - 13) and 36.7 months (95% CI, 23.6 - 43.9), respectively. No statistical differences in PFS or OS were observed between gefitinib and erlotinib as the 2^ndEGFR-TKI (PFS, P = 0.23 and OS, P = 0.052). The toxicities associated with the 2^ndEGFR-TKI were generally acceptable and comparable to those observed for the initial gefitinib therapy.</p> <p>Conclusions</p> <p>Our results indicate that a 2^ndEGFR-TKI treatment can be an effective treatment option for gefitinib responders.</p

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

<p>Abstract</p> <p>Background</p> <p>Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC). Few treatment options are available for NSCLC patients who have responded to gefitinib treatment and demonstrated tumor progression. The present study was conducted to evaluate the efficacy and toxicity of the 2^ndEGFR-TKI administration.</p> <p>Methods</p> <p>We retrospectively analyzed 11 patients who had obtained a partial response (PR) or stable disease (SD) with gefitinib treatment and were re-treated with EGFR-TKI after failure of the initial gefitinib treatment.</p> <p>Results</p> <p>Three patients (27%) were treated with gefitinib as the 2^ndEGFR-TKI, and 8 patients (73%) received erlotinib. Only one patient (9%) showed PR, 7 (64%) achieved SD, and 3 (27%) had progressive disease. The disease control rate was 73% (95% CI, 43% - 91%) and the median progression-free survival was 3.4 months (95% CI, 2 - 5.2). The median overall survival from the beginning of the 2^ndEGFR-TKI and from diagnosis were 7.3 months (95% CI, 2.7 - 13) and 36.7 months (95% CI, 23.6 - 43.9), respectively. No statistical differences in PFS or OS were observed between gefitinib and erlotinib as the 2^ndEGFR-TKI (PFS, P = 0.23 and OS, P = 0.052). The toxicities associated with the 2^ndEGFR-TKI were generally acceptable and comparable to those observed for the initial gefitinib therapy.</p> <p>Conclusions</p> <p>Our results indicate that a 2^ndEGFR-TKI treatment can be an effective treatment option for gefitinib responders.</p

Cs-Beta with an Al-rich composition as a highly active base catalyst for Knoevenagel condensation

Ion-exchange of an Al-rich zeolite beta, synthesized by organic structure-directing agent-free method (Beta-OF), was studied for application as a base catalyst. While the as-synthesized Beta-OF in Na-form itself had base sites and showed moderate catalytic activity for Knoevenagel condensation, the ion-exchange with Cs+ improved the catalytic activity. For Knoevenagel condensation of benzaldehyde with ethyl acetoacetate, the catalytic activity of Beta-OF ion-exchanged with Cs+ largely surpassed that of the conventional zeolite beta with less Al content. CO2-TPD and IR observation with chloroform as a probe molecule revealed that the Cs-exchanged Beta-OF had strong base sites comparable to Cs-exchanged Y zeolite. Base strength of Beta-OF was stronger than that expected by Sanderson's theory. A local high density of Al atoms in the framework of Beta-OF resulted in the unexpected base property and high catalytic activity